Platelet antiaggregants in the treatment and prevention of ischemic stroke
https://doi.org/10.14412/2074-2711-2013-2456
Abstract
The review of literature gives current views on the role of antiplatelet therapy in the treatment and secondary prevention of ischemic stroke. Relying on the data of evidence-based medicine, the author provides analytical characteristics of all platelet antiaggregants that have been put through worldwide clinical trials. The benefits and risks of each agent are shown in both monotherapy and combination therapy. The basic principles of choice of antiplatelet drugs for patients with acute stroke and postischemic stroke are outlined.
About the Author
Andrei Viktorovich Fonyakin
Neurology Research Center, Russian Academy of Medical Sciences, Moscow
Russian Federation
Russian Federation
References
1. <div><p>Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза. Клинические рекомендации ВНОК. Кардиоваскулярная терапия и профилактика. 2009;8(6). Приложение 3. [Diagnostika i korrektsiya narusheniy lipidnogo obmena s tsel'yu profilaktiki i lecheniya ateroskleroza. Klinicheskie rekomendatsii VNOK. Kardiovaskulyarnaya terapiya i profilaktika. 2009;8(6). Prilozhenie 3.]</p><p>Суслина ЗА, Гераскина ЛА, Фонякин А.. Артериальная гипертония и инсульт: связь и перспективы профилактики. Атмосфера. Кардиология 2001;1:5–7. [Suslina ZA, Geraskina LA, Fonyakin A.. Arterial'naya gipertoniya i insul't: svyaz' i perspektivy profilaktiki. Atmosfera. Kardiologiya 2001;1:5–7.]</p><p>Антитромботическая терапия у больных со стабильными проявлениями атеротромбоза. Российские рекомендации. Кардиоваскулярная терапия и профилактика. 2009;8 приложение 6:20. [Antithromlotic therapy in patients with stable manifestations of atherothrombosis. Russian advice. Kardiovaskulyarnaya terapiya i profilaktika. 2009;8 prilozhenie 6:20.]</p><p>Matias-Guiu J, Ferro JM, Alvarez-Sabin J et al. Comparison of triflusal and aspirin for prevention of vascular events in patients after cerebral infarction. The TACIP study: a randomized, double-blind, multicenter trial. Stroke. 2003;34(4):840–8. DOI: http://dx.doi.org/10.1161%2F01.STR.0000063141.24491.50. Epub 2003 Mar 20.</p><p>Costa J, Ferro JM, Matias-Guiu J et al. Trifluzal for preventing serious vascular events in people at high risk. Stroke. 2006;37;2193–5. DOI: http://dx.doi.org/10.1002%2F14651858.CD004296.</p><p>Huang Y, Cheng Y, Wu J et al. Cilostazol as an alternative to aspirin after ischaemic stroke: a randomized double blind pilot study. Lancet Neurol. 2008;7(6):494–9. DOI: 10.1016/S1474-4422(08)70094-2. Epub 2008 May 2.</p><p>Shinohara Y, Nishimaru K, Sawada T et al. Sarpogrelate-aspirin comparative clinical study for efficacy and safety in secondary prevention of cerebral infarction (C-ACCES). Stroke. 2008;39(6):1827–33. DOI: 10.1161/STROKEAHA.107.505131. Epub 2008 Apr 3.</p><p>CAST (Chinese Acute Stroke Trial) Collaborative Group. CAST: randomized placebo-controlled trial of early aspirin use in 20,000 patients with acute ischemic stroke. Lancet. 1997;349(9066):1641–9.</p><p>IST (International Stroke Trial) Collaborative Group. The International Stroke Trial (IST): a randomized trial of aspirin, subcutaneous heparin, both, or neither among 19,435 patients with acute ischemic stroke. Lancet. 1997;349:1569–81.</p><p>Chen ZM, Sandercock P, Pan HC et al. Indication for early aspirin use in acute ischemic stroke. A combined analysis of 40 000 randomized patients from the chines acute stroke trial and the international stroke trial. Stroke. 2000;31(6):1240–9.</p><p>The European Stroke Organization (ESO) Executive Committee and the ESO Writing Committee: Guidelines for management of ischaemic stroke and transient ischaemic attacks 2008. Cerebrovasc Dis. 2008;25(5):457–507. DOI: 10.1159/000131083. Epub 2008 May 6.</p><p>Furie KL, Kasner SE, Adams RJ et al. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack. AHA/ASA Guideline. Stroke. 2011;42(1):227–76. DOI: 10.1161/STR.0b013e3181f7d043. Epub 2010 Oct 21.</p><p>Antithrombotic Tralists` Collaboration. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction and stroke in high risk patients. BMJ. 2002;324(7329):71–86.</p><p>Суслина ЗА, Фонякин АВ, Гераскина ЛА. Ишемический инсульт и сердце: от патогенеза к профилактике. Клиническая фармакология и терапия. 2003;5:47–51. [Suslina ZA, Fonyakin AV, Geraskina LA. Ishemicheskiy insul't i serdtse: ot patogeneza k profilaktike. Klinicheskaya farmakologiya i terapiya. 2003;5:47–51.]</p><p>Фонякин АВ, Гераскина ЛА, Суслина ЗА. Сравнительная оценка постоянной и пароксизмальной фибрилляции предсердий в патогенезе кардиоцеребральной эмболии. Кардиология. 2002;7:4–6. [Fonyakin AV, Geraskina LA, Suslina ZA. Sravnitel'naya otsenka postoyannoy i paroksizmal'noy fibrillyatsii predserdiy v patogeneze kardiotserebral'noy embolii. Kardiologiya. 2002;7:4–6.]</p><p>Фонякин АВ, Гераскина ЛА, Суслина ЗА. Кардиальная патология при различных патогенетических подтипах ишемического инсульта. Клиническая медицина. 2002;1:25–8. [Fonyakin AV, Geraskina LA, Suslina ZA. Kardial'naya patologiya pri razlichnykh patogeneticheskikh podtipakh ishemicheskogo insul'ta. Klinicheskaya meditsina. 2002;1:25–8.]</p><p>Furie KL, Goldstein LB, Albers GW. et al. Oral antithrombotic agents for the prevention of stroke in nonvalvular atrial fibrillation: a science advisory for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2012;43(12):3442–53. DOI: 10.1161/STR.0b013e318266722a. Epub 2012 Aug 2.</p><p>Gent M., Blakely J.A., Easton J.D. et al. The Canadian American Ticlopidin Study (CATS) in thromboembolic stroke. Lancet. 1989;1:1215–20.</p><p>Hass WK, Easton JD, Adams HP et al. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients: Ticlopidin Aspirin Stroke Study Group. N Engl J Med. 1989;321(8):501–7.</p><p>Gorelick PB, Richardson D, Kelly M et al. Aspirin and ticlopidine for prevention of recurrent stroke in black patients: a randomized trial. JAMA. 2003;289(22):2947–57. DOI: http://dx.doi.org/10.1001%2Fjama.289.22.2947.</p><p>CAPRIE Steering Committee. A randomized, blinded trial of clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE). Lancet. 1996;348(9038):1329–39.</p><p>Bhatt DL, Fox KA, Hacke W et al. CHARISMA investigators: Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006;354(16):1706–17. Epub 2006 Mar 12.</p><p>Diener HC, Bogousslavsky J, Brass LM et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomized, double-blind, placebo-controlled trial. Lancet. 2004;364(9431):331–7.</p><p>Diener HC, Sacco RL, Yusuf S; Steering Committee; PROFESS Study Group. Rationale, design and baseline data of a randomized, double-blind, controlled trial comparing two Antithrombotic regimen (a fixed-dose combination of extended-release dipyridamole plus ASA with clopidogrel) and telmisartan versus placebo in patients with stroke. The Prevention Regimen for Effectively Avoiding Second Strokes Trial (PROFESS). Cerebrovasc Dis. 2007;23(5–6):368–80. Epub 2007 Feb 26.</p><p>Diener HC, Cunha L, Forbes C et al. European Stroke Prevention Study 2 (ESPS2). Dipyridaml and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci. 1996;143:1–13.</p><p>Kennedy J, Ryckborst KJ, Eliasziw M et al. Fast assessment of stroke and transient ischaemic attack to prevent early recurrence (FASTER): a randomised controlled pilot trial. Lancet Neurol. 2007;6(11):961–9. DOI: http://dx.doi.org/10.1016%2FS1474-4422%2807%2970250-8.</p><p>The Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) Trial Investigators. Effect of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345:494–502.</p><p>The ESPS Group. The European Stroke Prevention Study (ESPS): principal end-points. Lancet. 1987;2(8572):1351–4.</p><p>Verro P, Gorelick PB, Nguyen D. Aspirin plus dipiridamol versus aspirin for prevention of vascular events after stroke or TIA. Meta-analysis. Stroke. 2008;39(4):1358–63. DOI: 10.1161/STROKEAHA.107.496281. Epub 2008 Mar 6.</p><p>The ESPRIT study group. Aspirin plus dipyridamole versus aspirin alone after cerebral ischemia of arterial origin (ESPRIT): randomized controlled trial. Lancet. 2006;367(9523):1665–73.</p></div><br />
Review
For citations:
Fonyakin A.V. Platelet antiaggregants in the treatment and prevention of ischemic stroke. Neurology, Neuropsychiatry, Psychosomatics. 2013;5(4):54-59. (In Russ.) https://doi.org/10.14412/2074-2711-2013-2456
Views: 833
Email this article 